Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
NCT05668962
Adenocarcinoma, Adenocarcinoma, Follicular
Washington D.C., District of Columbia, United States
View Trial DetailsNCT Number: NCT06439745
In absence of nodal metastases or aggressive features, thyroid lobectomy (TL) should be preferred over total thyroidectomy (TT) for small unifocal papillary thyroid carcinoma (PTC). However, occult, despite non-microscopic (>2 mm), nodal metastases may be present in clinically node-negative (cN0) PTCs.
Among 4216 thyroidectomies for malignancy (2014-2023), 110 (2.6%) TL plus ipsilateral central neck dissection (I-CND) were scheduled for unifocal cT1b/small cT2 (<3 cm) cN0 PTCs.
Nodes frozen section examination (FSE) was performed: when positive, completion thyroidectomy (CT) was accomplished during the same procedure. In presence of aggressive pathologic features, CT was suggested within 6 months from index operation.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Although its incidence has increased in recent decades, the prognosis is excellent due to the indolent nature of the disease. Despite that, recurrence rate of PTC remains common. Nowadays, the correct extent of thyroidectomy remains controversial. However, several studies demonstrated no significant differences in terms of disease-free survival (DFS) and loco-regional recurrence (LRR) in differentiated thyroid carcinoma (DTC) > 1cm after thyroid lobectomy (TL) vs total thyroidectomy (TT). In absence of preoperative high-risk features (HRFs), the most recent NCCN and ATA guidelines consider unifocal 1-4 cm PTCs eligible for TL. However, many of HRFs are highlighted only after pathological examination: positive nodal status, aggressive tumor subtype, multifocality, microscopic extrathyroidal extension (ETE), positive margin and lymphovascular invasion (LVI).
Recent retrospective series showed that up to 59% of preoperative low risk PCTs were upgraded to higher risk category after pathological examination. Current recommendations could potentially increase the need for re-operation, in terms of completion thyroidectomy (CT) and subsequent administration of RAI in order to reduce the risk of LRR. Among the HRFs, no preoperative clinical parameter is a predictor of nodal disease. However, occult lymph node metastases (LNMs) may be found in 31-62% of patients subjected to prophylactic CND (p-CND). The risk of complications (hypoparathyroidism and laryngeal nerve injury) is the main matter against bilateral p-CND in unifocal node negative PCT. According to a recent systematic review, basing on prevalence of occult central LNM by tumor size, ipsilateral CND (I-CND) may be justified in all PTC patients. Since isolated contralateral metastases are rare, a routine use of frozen section examination (FSE) of I-CND may allow a more accurate staging with a reduction of morbidity. Although p-CND is not usually recommended in patients with clinically unifocal cT1b/T2 node negative PTC, we supposed that the evaluation of LN status through FSE of I-CND may significantly contribute to risk stratification and consequently to modulate the extension of surgical treatment.
In this retrospective study we aim to evaluate the result of this strategy to intraoperatively identify patients who may benefit from TT with bilateral CND (B-CND), reducing the need of second step CT and, theoretically, the risk of LRR.
Among 4176 patients who underwent thyroidectomy for malignancy between September 2014 and September 2023 at Fondazione Policlinico Universitario A. Gemelli - Rome, we identified 110 patients scheduled for TL plus I-CND for clinically intrathyroidal unifocal cT1b/small cT2 node negative PTC. Every patient was informed of the risks and benefits of TL and TT, based on available guidelines.
Inclusion criteria
were: age>18; classic papillary carcinoma and variants; clinically unifocal and intrathyroidal PTC; clinical tumor size >1 cm and ≤3 cm; no clinical evidence of LN involvement.
Exclusion criteria
were: age < 18 years; prior head or neck irradiation; family history of thyroid carcinoma; clinical evidence of multifocality, extrathyroidal extension or LN metastases; follow-up < 6 months.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: September 2014-September 2023
Evaluation of histopathologic risk factors in patients with papillary thyroid carcinoma, consisting of rate of nodal metastases, aggressive variants, lympho-angioinvasion, extranodal extension, multifocalty, positive resection status, in order to tailor surgical strategy (completion thyroidectomy)
Time frame: September 2014-September 2023
Evaluation of the rate of disease recurrence among the patients' cohort
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Other
More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated
Acronym: cN0PTC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05668962
Adenocarcinoma, Adenocarcinoma, Follicular
Washington D.C., District of Columbia, United States
View Trial DetailsNCT07659717
Adenocarcinoma, Adenocarcinoma, Papillary
Palermo, Sicily, Italy
View Trial DetailsNCT00001160
Adenocarcinoma, Adenocarcinoma, Follicular
Bethesda, Maryland, United States
View Trial DetailsNCT04948437
Adenocarcinoma, Adenocarcinoma, Follicular
Taipei, Taiwan
View Trial Details